Gedeon Richter

GEDEON RICHTER NEWSROOM (7 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2023 2020 2018 2014 2013

Vienna Stock Exchange Launches Three New Thematic Indices to Reflect Long-Term Investment Trends in Central and Eastern Europe

PRESS RELEASE -- 27, September 2023

(IN BRIEF) Vienna Stock Exchange has introduced three new thematic indices to reflect long-term investment trends in the Central and Eastern European (CEE) region. These indices are CECE Reshoring, CECE Commodity Producers, and CECE Clean Energy. CECE Reshoring comprises companies … Read the full press release →

Palette Life Sciences AB and Gedeon Richter Plc. Receive National Marketing Authorization in the United Kingdom for Novel Pain Relief Product, LIDBREE™

PRESS RELEASE -- 5, August 2020

(PRESS RELEASE) SANTA BARBARA, CALIF., U.S.A. / BUDAPEST / STOCKHOLM, 5-Aug-2020 — /EuropaWire/ — Palette Life Sciences AB (‘Palette’) with Gedeon Richter Plc. (‘Richter’), today announced that as a part of a decentralised regulatory procedure including thirty European Union Economic … Read the full press release →

Medicinal Chemistry: Peter D.J. Grootenhuis is the recipient of the 2018 IUPAC-Richter Prize for outstanding creative contributions in the treatment of cystic fibrosis

PRESS RELEASE -- 30, January 2018

The 2018 IUPAC-Richter Prize in Medicinal Chemistry has been awarded to Peter D.J. Grootenhuis. BUDAPEST, 30-Jan-2018 — /EuropaWire/ — Peter D.J. Grootenhuis received this award in recognition of his outstanding creative contributions to the invention, discovery, and development of the medicine … Read the full press release →

Gedeon Richter Plc. and Forest Laboratories, Inc. announce positive Phase IIb studies for cariprazine in both bipolar depression and major depressive disorder

PRESS RELEASE -- 1, April 2014

Budapest and New York, 1-4-2014 — /EuropaWire/ — Gedeon Richter Plc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. … Read the full press release →

EIB injects EUR 150m into Gedeon Richter’s R&D operations in Hungary, one of the biggest research projects in central Europe

PRESS RELEASE -- 7, May 2013

We are supporting research and development into innovative drug treatments in Hungary 7-5-2013 — /europawire.eu/ — For well over 100 years, Hungarian pharmaceutical company Gedeon Richter has been working to improve their clients’ health and quality of life. It has stepped … Read the full press release →

Gedeon Richter and Orion Corporation to collaborate on the discovery and development of new chemical entities in the field of cognitive disorders

PRESS RELEASE -- 27, March 2013

BUDAPEST and ESPOO, 27-3-2013 — /europawire.eu/ — Gedeon Richter Plc. (‘Richter’) and Orion Corporation (‘Orion’) today announced that the two companies have entered into a comprehensive and long term collaboration agreement for the discovery and development of new chemical entities in … Read the full press release →

Gedeon Richter Plc and Rxmidas Pharmaceuticals Co. Ltd. form a new Joint Venture seeking direct presence on the Chinese pharmaceutical market

PRESS RELEASE -- 25, March 2013

25-3-2013 — /europawire.eu/ — Gedeon Richter Plc. (’Richter’) announces today that it has signed a series of agreements with the owners of its marketing partner, Rxmidas Pharmaceuticals Co. Ltd. (’Rxmidas’), targeting a reshaped and stronger direct presence on the Chinese pharmaceutical … Read the full press release →